Burcon hits record protein output, expands to more than 20 customers

Burcon NutraScience is making its case the old-fashioned way: by running more protein through the plant and getting it into more customers’ hands. Over the past several weeks, the Vancouver company said it reached record production, lifting average daily output by about 40% versus its calendar first-quarter average, while expanding its commercial footprint to more than 20 buying customers across ready-to-mix beverages, nutrition products and plant-based food applications.

That production jump matters because Burcon has spent years positioning its ingredient platform around functionality, taste and solubility, not just protein content. The company said demand is now coming across its full portfolio, including Peazzaz®, FavaProTM and Puratein®, which it is pitching as application-ready ingredients for multiple formats. Burcon and its manufacturing partner, RE ProMan LLC, are also evaluating additional capacity expansion opportunities to support future customer requirements, a sign that the company sees current demand as more than a one-off spike.

The manufacturing story has been building since RE ProMan completed the acquisition of a protein production facility in Galesburg, Illinois on March 10, 2025. Burcon later said that within 90 days of commissioning the site it achieved first commercial production of its next-generation proteins and secured a $6.8 million multi-year production agreement. That sequence, facility acquisition, commissioning, first commercial output and a longer-term contract, gives the company a much more concrete industrial base than the pilot-scale narrative that often hangs around emerging ingredient companies.

The financial backdrop shows why scale is now the real test. For fiscal 2025, Burcon reported revenue of C$381,000 from protein isolate sales and contract research services, up from C$184,000 in royalty revenue in the prior year. Even as revenue moved in the right direction, the company posted a net loss of C$8.3 million for the year ended March 31, 2025, with an accumulated deficit of C$150.3 million. For the nine months ended December 31, 2025, Burcon reported a net loss of C$10.7 million and net cash used in operating activities of C$6.2 million.

Burcon has also said its pipeline included more than 200 new customer projects in a December 2025 shareholder letter, and it plans to show its high-purity plant protein lineup at IFT FIRST in Chicago. In a market crowded with promising formulations, the company is arguing that dependable output, not just promising science, is what turns a protein supplier into a serious commercial partner.